NDAORAL-28TABLET
Approved
Dec 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
CYCLESSA (desogestrel; ethinyl estradiol) by Aspen Surgical is clinical pharmacology pharmacodynamics combined oral contraceptives act by suppression of gonadotropins. Approved for pregnancy in women. First approved in 2000.
Drug data last refreshed 8h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CYCLESSA is an oral combined hormonal contraceptive containing desogestrel 0.15 mg and ethinyl estradiol 0.03 mg in a 28-day cyclic regimen. It prevents pregnancy primarily through suppression of gonadotropins and ovulation, with secondary mechanisms including cervical mucus thickening and endometrial changes. The active ingredient desogestrel is rapidly metabolized to 3-keto-desogestrel, which exhibits high progestational activity with minimal androgenicity.
LOE Approaching
Product approaching loss of exclusivity with limited market intelligence on spending; brand team focus likely shifting toward retention strategies or pipeline transition planning.
Mechanism of Action
CLINICAL PHARMACOLOGY Pharmacodynamics Combined oral contraceptives act by suppression of gonadotropins. Although the primary mechanism of this action is inhibition of ovulation, other alterations include changes in the cervical mucus, which increase the difficulty of sperm entry into the uterus,…
Worked on CYCLESSA at Aspen Surgical? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.